AtG Therapeutics
AtG Therapeutics is a pre-clinical stage biotech focused on developing innovative therapies to treat advanced cancer by targeting tumor metabolic adaptation. The company aims to advance therapies to clinical trials, improve patient lives, and position itself in the market of targeted oncological treatments through licensing its technology to large pharmaceutical companies. It is a spin-off from IDIBELL and ICO, supported by various national and international entities, and engaged in cutting-edge research on resistance mechanisms and tumor malignization.
Industries
Nr. of Employees
small (1-50)
AtG Therapeutics
Hospital Duran i Reynals (3rd floor). Av. Gran Via 199, 08908. Barcelona, Spain.
Products
Preclinical small-molecule tumor adaptation inhibitor candidate
A preclinical small-molecule therapeutic candidate designed to inhibit Tumor Adaptation Factor-1 (TA-1) to reduce tumor adaptation and resistance in advanced solid tumors.
Companion diagnostic for plasma biomarker detection
A diagnostic assay intended to detect a circulating biomarker in plasma to identify patients likely to respond to TA-1 inhibitor therapy.
Preclinical small-molecule tumor adaptation inhibitor candidate
A preclinical small-molecule therapeutic candidate designed to inhibit Tumor Adaptation Factor-1 (TA-1) to reduce tumor adaptation and resistance in advanced solid tumors.
Companion diagnostic for plasma biomarker detection
A diagnostic assay intended to detect a circulating biomarker in plasma to identify patients likely to respond to TA-1 inhibitor therapy.
Services
Collaborative partnerships for co-development of therapeutic candidates and companion diagnostics with external partners and academic groups.
Engagement with investors and licensing discussions to fund preclinical development and out-license technologies to larger developers.
Collaborative partnerships for co-development of therapeutic candidates and companion diagnostics with external partners and academic groups.
Engagement with investors and licensing discussions to fund preclinical development and out-license technologies to larger developers.
Expertise Areas
- Cancer metabolic adaptation target discovery
- Preclinical oncology drug development
- Companion diagnostic development and biomarker validation
- Medicinal chemistry and lead optimization
Key Technologies
- Small-molecule drug discovery
- Plasma biomarker assays
- Companion diagnostic assays
- Lead optimization (medicinal chemistry)
News & Updates
AtG Therapeutics has announced the appointment of Itziar Canamasas, PhD, as its new CEO. Dr. Canamasas brings over 20 years of experience in the pharmaceutical industry, focusing on global commercialization, strategic life-cycle development, corporate strategy, and country leadership.
The company has secured more than 500,000 euros in a funding round to develop therapeutic alternatives for advanced cancers and a screening system for patients.
AtG Therapeutics received a grant from FIPSE to finance feasibility studies of their health innovations.
AtG Therapeutics has announced the appointment of Itziar Canamasas, PhD, as its new CEO. Dr. Canamasas brings over 20 years of experience in the pharmaceutical industry, focusing on global commercialization, strategic life-cycle development, corporate strategy, and country leadership.
The company has secured more than 500,000 euros in a funding round to develop therapeutic alternatives for advanced cancers and a screening system for patients.
AtG Therapeutics received a grant from FIPSE to finance feasibility studies of their health innovations.